Bellicum Pharmaceuticals Completes Series C Funding
August 28, 2014
Bellicum Pharmaceuticals has raised $55 million in a Series C financing. The oversubscribed round was raised from a large contingent of investors including RA Capital Management, Remeditex Ventures, Redmile Group and venBio Select, among others. The biotech company is developing cellular immunotherapies to treat cancers and other chronic and life-threatening diseases. The funding will be used to accelerate the clinical development of BPX-501, a treatment for leukemia/lymphoma and non-malignant genetic diseases. In January of this year, the company raised a Series B round at a valuation close to $82 million.